Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Restructuring Costs (2022 - 2025)

BridgeBio Pharma's Restructuring Costs history spans 4 years, with the latest figure at $11.4 million for Q4 2025.

  • For Q4 2025, Restructuring Costs rose 142.06% year-over-year to $11.4 million; the TTM value through Dec 2025 reached $21.3 million, up 36.8%, while the annual FY2025 figure was $21.3 million, 36.8% up from the prior year.
  • Restructuring Costs for Q4 2025 was $11.4 million at BridgeBio Pharma, up from $8.8 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $22.7 million in Q1 2022 and bottomed at $272000.0 in Q3 2023.
  • The 4-year median for Restructuring Costs is $4.1 million (2023), against an average of $5.5 million.
  • The largest annual shift saw Restructuring Costs crashed 94.58% in 2023 before it skyrocketed 2618.75% in 2024.
  • A 4-year view of Restructuring Costs shows it stood at $7.7 million in 2022, then tumbled by 90.2% to $754000.0 in 2023, then surged by 522.41% to $4.7 million in 2024, then soared by 142.06% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Restructuring Costs are $11.4 million (Q4 2025), $8.8 million (Q3 2025), and $712000.0 (Q2 2025).